These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12199673)

  • 21. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
    Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
    Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?
    Hausammann S; Vogel M; Kremer Hovinga JA; Lacroix-Desmazes S; Stadler BM; Horn MP
    PLoS One; 2013; 8(4):e60688. PubMed ID: 23626669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.
    Chansavang A; Philippe A; Bozinovic I; Ben Hadj Ali K; Smadja D; Helley D; Darnige L; Mauge L
    Ann Hematol; 2022 Nov; 101(11):2453-2460. PubMed ID: 36125542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII.
    Rothschild C; Amiral J; Adam M; Meyer D
    Haemostasis; 1990; 20(6):321-8. PubMed ID: 2129163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.
    Irigoyen MB; Primiani L; Felippo M; Candela M; Bianco RP; De Bracco MM; Galassi N
    Haemophilia; 2011 Mar; 17(2):267-74. PubMed ID: 21070488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haemophilia A and von Willebrand's disease.
    Goodeve AC; Rosén S; Verbruggen B
    Haemophilia; 2010 Jul; 16 Suppl 5():79-84. PubMed ID: 20590861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired haemophilia syndrome: pathophysiology and therapy.
    Elezović I
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
    Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
    Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
    Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
    Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
    Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.